Neoleukin Therapeutics, Inc. announced resignation of Robert Ho as Chief Financial Officer to pursue another opportunity, effective March 1, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.6 USD | +10.10% | +17.10% | +94.01% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+94.01% | 49Cr | |
+43.36% | 5.46TCr | |
-5.31% | 3.99TCr | |
+14.75% | 2.69TCr | |
-12.56% | 2.62TCr | |
-22.45% | 1.88TCr | |
+25.12% | 1.22TCr | |
+0.04% | 1.22TCr | |
+26.04% | 1.19TCr | |
-11.83% | 1.07TCr |
- Stock Market
- Equities
- NGNE Stock
- News Neurogene Inc.
- Neoleukin Therapeutics, Inc. Announces Resignation of Robert Ho as Chief Financial Officer, Effective March 1, 2022